Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
CONCLUSION: Early evidence suggests that dapagliflozin and empagliflozin are well tolerated in children. A clinical pharmacology rationale currently exists only for adolescents with diabetes mellitus.PROSPERO REGISTRATION NUMBER: CRD42023438162.PMID:38635113 | DOI:10.1007/s40272-024-00623-z (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 18, 2024 Category: Pediatrics Authors: Sebastiano A G Lava Craig Laurence Alessandro Di Deo Nicole Sekarski Michael Burch Oscar Della Pasqua Source Type: research
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
CONCLUSIONS: Five literature models effectively described adalimumab PK in this pediatric cohort, highlighting the potential for extrapolating existing models to the pediatric population. The new JIA model confirmed the effect of several known covariates and found a novel association for drug clearance with methotrexate use (lower) and uveitis (higher), which might have clinical relevance for personalized dosing in JIA.PMID:38630199 | DOI:10.1007/s40272-024-00629-7 (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 17, 2024 Category: Pediatrics Authors: Amara Nassar-Sheikh Rashid Femke Hooijberg Sandy C Bergkamp Mariken P Gruppen Taco W Kuijpers Mike Nurmohamed Theo Rispens Gertjan Wolbink J Merlijn van den Berg Dieneke Schonenberg-Meinema Ron A A Math ôt Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.PMID:38587585 | DOI:10.1007/s40272-024-00624-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 8, 2024 Category: Pediatrics Authors: Iris K Minichmayr Ursula Knaack Johannes Gojo Daniel Senfter Christine Haberler Amedeo A Azizi Lisa Mayr Markus Zeitlinger Andreas Peyrl Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Paediatr Drugs. 2024 Apr 2. doi: 10.1007/s40272-024-00626-w. Online ahead of print.ABSTRACTNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, mater...
Source: Paediatric Drugs - April 2, 2024 Category: Pediatrics Authors: Annette Gawron Roberts Noelle Younge Rachel Gottron Greenberg Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Paediatr Drugs. 2024 Apr 2. doi: 10.1007/s40272-024-00626-w. Online ahead of print.ABSTRACTNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, mater...
Source: Paediatric Drugs - April 2, 2024 Category: Pediatrics Authors: Annette Gawron Roberts Noelle Younge Rachel Gottron Greenberg Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Paediatr Drugs. 2024 Apr 2. doi: 10.1007/s40272-024-00626-w. Online ahead of print.ABSTRACTNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, mater...
Source: Paediatric Drugs - April 2, 2024 Category: Pediatrics Authors: Annette Gawron Roberts Noelle Younge Rachel Gottron Greenberg Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Paediatr Drugs. 2024 Apr 2. doi: 10.1007/s40272-024-00626-w. Online ahead of print.ABSTRACTNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, mater...
Source: Paediatric Drugs - April 2, 2024 Category: Pediatrics Authors: Annette Gawron Roberts Noelle Younge Rachel Gottron Greenberg Source Type: research
Neonatal Necrotizing Enterocolitis: An Update on Pathophysiology, Treatment, and Prevention
Paediatr Drugs. 2024 Apr 2. doi: 10.1007/s40272-024-00626-w. Online ahead of print.ABSTRACTNecrotizing enterocolitis (NEC) is a life-threatening disease predominantly affecting premature and very low birth weight infants resulting in inflammation and necrosis of the small bowel and colon and potentially leading to sepsis, peritonitis, perforation, and death. Numerous research efforts have been made to better understand, treat, and prevent NEC. This review explores a variety of factors involved in the pathogenesis of NEC (prematurity, low birth weight, lack of human breast milk exposure, alterations to the microbiota, mater...
Source: Paediatric Drugs - April 2, 2024 Category: Pediatrics Authors: Annette Gawron Roberts Noelle Younge Rachel Gottron Greenberg Source Type: research
Comparison of Deep and Moderate Neuromuscular Blockade for Major Laparoscopic Surgery in Children: A Randomized Controlled Trial
CONCLUSIONS: A deep NMB provided better operative conditions and similar recovery profiles compared with a moderate NMB as reversed with sugammadex in children undergoing major laparoscopic surgery.CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, No. ChiCTR2100053821.PMID:38512578 | DOI:10.1007/s40272-024-00622-0 (Source: Paediatric Drugs)
Source: Paediatric Drugs - March 21, 2024 Category: Pediatrics Authors: Guo Wei Yong-Xin Li Ying Chen Mei Diao John Wei Zhong Shou-Dong Pan Source Type: research
Comparison of Deep and Moderate Neuromuscular Blockade for Major Laparoscopic Surgery in Children: A Randomized Controlled Trial
CONCLUSIONS: A deep NMB provided better operative conditions and similar recovery profiles compared with a moderate NMB as reversed with sugammadex in children undergoing major laparoscopic surgery.CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, No. ChiCTR2100053821.PMID:38512578 | DOI:10.1007/s40272-024-00622-0 (Source: Paediatric Drugs)
Source: Paediatric Drugs - March 21, 2024 Category: Pediatrics Authors: Guo Wei Yong-Xin Li Ying Chen Mei Diao John Wei Zhong Shou-Dong Pan Source Type: research
